Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer

Completed · Phase 2

Conditions studied: Ovarian Neoplasms

In brief

The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every week in the treatment of patients with advanced ovarian cancer that is resistant to platinum-based chemotherapy.

Key facts

Study ID

NCT00038428

Run by

Telik

People needed

40

Starts

2001-06-01

Expected to finish

2005-07-01

Last updated by the study team

2011-07-25

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Histologic diagnosis of ovarian cancer
• Recurrent or persistent disease following primary therapy
• Measurable disease
• Prior treatment with at least one but no more than three prior chemotherapy regimens
• Resistant or refractory to platinum-based chemotherapy
• At least 18 years of age
• Good performance status (ECOG 0 to 1)
• Adequate liver, renal and bone marrow function

You may not qualify if…

• Pregnant or currently breast feeding
• Treatment with chemotherapy or immunotherapy within four weeks
• Prior radiation to the whole pelvis

Where it is running

• USC/Norris Comprehensive Cancer Center — Los Angeles, California, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• M.D. Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.